RLMD News and Press, Relmada Therapeutics Inc. From 04/29/21

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting PR Newswire NEW YORK , April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing dis...

Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit PR Newswire NEW YORK , April 28, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ce...

Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021 PR Newswire NEW YORK , April 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RL...

Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder Long-Term Safety Study Also Underway Top-line Data from Both Pivotal Studies Expected in First Half of 2022 PR Newswi...

Relmada Therapeutics, Inc. (RLMD) Q4 2020 Earnings Conference Call March 23, 2021 16:30 ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Marc Goodman ...

Relmada Therapeutics (RLMD): FY GAAP EPS of -$3.81 misses by $0.25.Cash, cash equivalents, and short-term investment of $117.1M.Press Release For further details see: Relmada Therapeutics EPS misses by $0.25

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results Phase 3 Program for REL-1017 as Adjunctive Treatment for Major Depressive Disorder Initiated Multiple Data Readouts Anticipated Over Next Several Quarters Compa...

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021 Relmada to host conference call and webcast on Tuesday, March 23, 2021 at 4:30 PM Eastern Time PR Newswire NEW YORK , March...

Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference PR Newswire NEW YORK , March 11, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the c...

Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference PR Newswire NEW YORK , Feb. 23, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the ce...